Subsidy Information and Financing Scheme MSHLNeratinib Tablet 40 mg 1) In combination with capecitabine for treating patients with advanced or metastatic HER2-positive... See all × MSHLNeratinib Tablet 40 mg 1) In combination with capecitabine for treating patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. 2) Extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Treatment of neratinib should be initiated within 1 year after completion of trastuzumab therapy.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 40 mg National Cancer Centre National University Hospital